Management of Persistent Asthma Uncontrolled on Maximum Dose Dulera and SABA
Stepwise Approach to Escalation
- For patients aged 12 years and older with uncontrolled persistent asthma on ICS-LABA, adding LAMA to the existing ICS-LABA combination is conditionally recommended over continuing the same dose of ICS-LABA alone, as per the American Academy of Pediatrics 1, 2, 3, 4
- The American Academy of Allergy, Asthma, and Immunology recommends verifying adherence to current medications, proper inhaler technique, environmental control measures, and addressing comorbid conditions before adding medications, such as LAMA 4, 5
Alternative/Additional Considerations
- For patients with documented IgE-mediated allergic asthma, the American College of Allergy, Asthma, and Immunology recommends considering adding omalizumab to the treatment regimen, which has been shown to reduce asthma exacerbations 6, 5
- The American Thoracic Society conditionally recommends using ICS-formoterol as both daily controller and reliever therapy for patients aged 12 years and older with moderate to severe persistent asthma, over higher-dose ICS-LABA as daily controller with SABA for quick relief 1, 2, 3, 4
Important Safety Considerations
- The National Asthma Education and Prevention Program recommends that using SABA more than 2 days per week for symptom relief indicates inadequate control and confirms the need for treatment intensification, and frequent SABA use should prompt immediate escalation of controller therapy 7, 5
- The American Academy of Pediatrics recommends against adding LAMA to ICS alone, and against using LABA as monotherapy due to increased severe exacerbations and deaths 1, 2, 3, 4, 6, 5
Clinical Nuances
- The recommendation to add LAMA to ICS-LABA has moderate certainty of evidence and is a conditional recommendation, with a reduction in exacerbation risk (RR 0.67, 95% CI 0.48-0.92) 1, 2, 3, 4
- The American College of Chest Physicians recommends reassessing asthma control at 2-6 weeks after adding LAMA, and considering biologic therapy if control remains inadequate despite triple therapy plus verification of adherence/technique/environmental factors 4, 6, 5